AU2007307080B2 - Methods for treating cancer with MVA - Google Patents

Methods for treating cancer with MVA Download PDF

Info

Publication number
AU2007307080B2
AU2007307080B2 AU2007307080A AU2007307080A AU2007307080B2 AU 2007307080 B2 AU2007307080 B2 AU 2007307080B2 AU 2007307080 A AU2007307080 A AU 2007307080A AU 2007307080 A AU2007307080 A AU 2007307080A AU 2007307080 B2 AU2007307080 B2 AU 2007307080B2
Authority
AU
Australia
Prior art keywords
mva
antigen
taxane
cells
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007307080A
Other languages
English (en)
Other versions
AU2007307080A1 (en
Inventor
Alain Delcayre
Reiner Laus
Stefanie Mandl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of AU2007307080A1 publication Critical patent/AU2007307080A1/en
Assigned to BN IMMUNOTHERAPEUTICS INC. reassignment BN IMMUNOTHERAPEUTICS INC. Amend patent request/document other than specification (104) Assignors: BN IMMUNOTHERAPEUTICS INC.
Assigned to BAVARIAN NORDIC INC. reassignment BAVARIAN NORDIC INC. Amend patent request/document other than specification (104) Assignors: BN IMMUNOTHERAPEUTICS INC.
Application granted granted Critical
Publication of AU2007307080B2 publication Critical patent/AU2007307080B2/en
Assigned to BAVARIAN NORDIC A/S reassignment BAVARIAN NORDIC A/S Request for Assignment Assignors: BAVARIAN NORDIC INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2007307080A 2006-10-06 2007-10-05 Methods for treating cancer with MVA Active AU2007307080B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85003106P 2006-10-06 2006-10-06
US60/850,031 2006-10-06
PCT/US2007/021436 WO2008045346A2 (en) 2006-10-06 2007-10-05 Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer

Publications (2)

Publication Number Publication Date
AU2007307080A1 AU2007307080A1 (en) 2008-04-17
AU2007307080B2 true AU2007307080B2 (en) 2014-01-09

Family

ID=39283388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007307080A Active AU2007307080B2 (en) 2006-10-06 2007-10-05 Methods for treating cancer with MVA

Country Status (11)

Country Link
US (2) US7807146B2 (OSRAM)
EP (2) EP2073837B1 (OSRAM)
JP (2) JP5964540B2 (OSRAM)
AU (1) AU2007307080B2 (OSRAM)
CA (1) CA2665068C (OSRAM)
DK (2) DK2596801T3 (OSRAM)
ES (1) ES2500465T3 (OSRAM)
IL (1) IL197633A (OSRAM)
NZ (2) NZ575388A (OSRAM)
PT (1) PT2073837E (OSRAM)
WO (1) WO2008045346A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3163902A (en) * 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
EP2073837B1 (en) * 2006-10-06 2014-06-25 Bavarian Nordic Inc. Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
WO2012059376A1 (en) * 2010-11-02 2012-05-10 Telefonaktiebolaget L M Ericsson (Publ) Methods and devices for media description delivery
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
AU2013331328B2 (en) * 2012-10-19 2018-05-31 Bavarian Nordic A/S Methods and compositions for the treatment of cancer
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
US10171528B2 (en) 2013-07-03 2019-01-01 Koninklijke Kpn N.V. Streaming of segmented content
CA3205348A1 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3706768A4 (en) * 2017-11-06 2021-08-25 Memorial Sloan Kettering Cancer Center USE OF THE HEAT-INACTIVATED VACCINE VIRUS AS A VACCINE IMMUNE ADJUDENT
AU2019339535B2 (en) 2018-09-15 2025-11-20 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188834A1 (de) * 2000-08-30 2002-03-20 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/neu-Gens
WO2004058279A1 (en) * 2002-12-27 2004-07-15 Zhang, Xiaoli Composition comprising scutellaria baicalensis and their uses thereof
US20040141958A1 (en) * 1998-10-05 2004-07-22 M&E Biotech A/S Novel methods for therapeutic vaccination

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
DE19729279A1 (de) 1997-07-09 1999-01-14 Peter Hildebrandt Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt
AU3163902A (en) 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
US20040191218A1 (en) * 2001-09-26 2004-09-30 Emlen James W Pharmaceutical compositions and methods for treating cancer
AU2003276467A1 (en) * 2002-11-06 2004-06-07 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
US8663622B2 (en) 2002-12-16 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant vaccine viruses expressing IL-15 and methods using the same
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2004103301A2 (en) * 2003-05-16 2004-12-02 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
EA008827B1 (ru) 2003-06-25 2007-08-31 Фармекса А/С Очистка вариантов her-2
MXPA05013389A (es) * 2003-06-25 2006-03-17 Pharmexa As Purificacion de variantes her-2.
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
HUE030037T2 (en) 2005-02-23 2017-04-28 Bavarian Nordic As Use of modified anemic virus for rapid induction of immunity against gluten virus or other agents
EP2073837B1 (en) 2006-10-06 2014-06-25 Bavarian Nordic Inc. Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141958A1 (en) * 1998-10-05 2004-07-22 M&E Biotech A/S Novel methods for therapeutic vaccination
US20060008465A1 (en) * 1998-10-05 2006-01-12 Pharmexa A/S Novel methods for therapeutic vaccination
EP1188834A1 (de) * 2000-08-30 2002-03-20 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/neu-Gens
WO2004058279A1 (en) * 2002-12-27 2004-07-15 Zhang, Xiaoli Composition comprising scutellaria baicalensis and their uses thereof

Also Published As

Publication number Publication date
EP2073837B1 (en) 2014-06-25
JP2010505850A (ja) 2010-02-25
AU2007307080A1 (en) 2008-04-17
NZ597998A (en) 2013-08-30
IL197633A (en) 2017-03-30
WO2008045346A2 (en) 2008-04-17
EP2596801B1 (en) 2018-05-02
EP2596801A1 (en) 2013-05-29
IL197633A0 (en) 2011-08-01
PT2073837E (pt) 2014-09-22
US7807146B2 (en) 2010-10-05
WO2008045346A3 (en) 2009-06-04
US20080213302A1 (en) 2008-09-04
CA2665068C (en) 2016-01-05
NZ575388A (en) 2012-03-30
DK2073837T3 (da) 2014-09-29
ES2500465T3 (es) 2014-09-30
EP2073837A2 (en) 2009-07-01
JP6124822B2 (ja) 2017-05-10
US20110008294A1 (en) 2011-01-13
CA2665068A1 (en) 2008-04-17
US8313740B2 (en) 2012-11-20
JP5964540B2 (ja) 2016-08-03
JP2014129416A (ja) 2014-07-10
DK2596801T3 (en) 2018-08-13

Similar Documents

Publication Publication Date Title
AU2007307080B2 (en) Methods for treating cancer with MVA
JP7368305B2 (ja) 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法
CA2702586C (en) Use of mva to treat prostate cancer
AU2015259510B2 (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
RU2714142C2 (ru) Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки
US20150283220A1 (en) Methods and compositions for the treatment of cancer
HK1149709B (en) Use of mva to treat prostate cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BAVARIAN NORDIC A/S

Free format text: FORMER OWNER WAS: BAVARIAN NORDIC INC.